All In Biotech

NDA 206038 · Vertex Pharms INC

Orkambi

Ivacaftor, Lumacaftor · Oral · Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jul 2, 2015

Approved uses

4

Original approval plus efficacy supplements

Registered trials

136

60 Phase 3, 11 recruiting

FAERS reports

8,538

5,384 serious, 158 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 24, 2026.

ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. ORKAMBI is a combination of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, and lumacaftor, indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. ( 1 ) Limitations of Use: The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation. ( 1 ) Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation .

Mechanism: The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein. Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and...

Therapeutic areas: Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 13, 2024 Supplement 18 · Efficacy · priority review OrphanLabelLetter
  • Jan 25, 2018 Supplement 7 · Efficacy LetterLabel
  • Sep 28, 2016 Supplement 5 · Efficacy · priority review Breakthrough therapyLetterLabel
  • Jul 2, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
2 products under this application
  • ORKAMBI · IVACAFTOR 125MG; LUMACAFTOR 100MG · TABLET, ORAL · Prescription
  • ORKAMBI · IVACAFTOR 125MG; LUMACAFTOR 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivacaftor" as an intervention, any sponsor and status, largest first.

All 136 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infective pulmonary exacerbation of cystic fibrosis1,462
  • hospitalisation888
  • dyspnoea559
  • pulmonary function test decreased397
  • cough395
  • infection370
  • chest discomfort344
  • cystic fibrosis328
  • pneumonia269
  • malaise225
  • nasopharyngitis202
  • fatigue200

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2015613
20161,493
20171,499
20181,638
20191,989
2020728
2021169
2022121
2023120
202469
202547
202652

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Orkambi (Lumacaftor/IVacaftor)

2024 spending

$634K

Beneficiaries

n/a

28 claims

Per beneficiary

n/a

$202.15 per unit

View as table
YearSpending
2020$2,778,194
2021$1,483,307
2022$1,433,409
2023$1,094,041
2024$633,932

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 146 on PubMed

Sponsor: Vertex Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.